Evidence map›Paper›PMID 40357260›Full record

ArticleEuropean heart journal open2025

Reduced dose direct oral anticoagulants and time-in-therapeutic-range defined warfarin in new-onset atrial fibrillation: a report from the nationwide FinACAF study.

Alex Luojus, Mika Lehto, Olli Halminen, Ossi Lehtonen, Mikko Niemi, Konsta Teppo, Jaana Kuoppala, Jari Haukka, Jukka Putaala, Miika Linna and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in European heart journal open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Alex LuojusHeart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0001-7119-2781
Mika LehtoHeart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-8691-5142
Olli HalminenAalto University, Espoo, Finland.ORCID https://orcid.org/0000-0001-9266-8435
Ossi LehtonenUniversity of Eastern Finland, Kuopio, Finland.ORCID https://orcid.org/0009-0009-4914-1027
Mikko NiemiDepartment of Clinical Pharmacology and Individualized Drug Therapy Research Program, University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0003-4550-2189
Konsta TeppoTurku University Hospital and University of Turku, Finland.ORCID https://orcid.org/0000-0002-4460-0994
Jaana KuoppalaUniversity of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0009-0000-0569-058X
Jari HaukkaUniversity of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0003-1450-6208
Jukka PutaalaDepartment of Neurology, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0002-6630-6104
Miika LinnaAalto University, Espoo, Finland.ORCID https://orcid.org/0000-0002-7660-2484
Pirjo MustonenTurku University Hospital and University of Turku, Finland.ORCID https://orcid.org/0000-0003-1319-0248
Aapo AroHeart and Lung Center, Helsinki University Hospital and University of Helsinki, Helsinki, Finland.ORCID https://orcid.org/0000-0001-7030-6740
Juha HartikainenKuopio University Hospital and University of Eastern  Finland.ORCID https://orcid.org/0000-0003-0847-107X
Gregory Yoke Hong LipLiverpool Centre for Cardiovascular Science, University of Liverpool, Liverpool John Moores University and Liverpool Heart & Chest Hospital, Liverpool, UK.ORCID https://orcid.org/0000-0002-7566-1626
Kari Eino Juhani AiraksinenTurku University Hospital and University of Turku, Finland.ORCID https://orcid.org/0000-0002-0193-568X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aims: Direct oral anticoagulants (DOACs) at reduced dosage regimens are the first choice of ischaemic stroke (IS) prevention for patients with atrial fibrillation (AF) and elevated bleeding risk or renal insufficiency. We compared the outcomes of reduced dose DOACs and warfarin. Methods and results: We included all new-onset patients with AF in Finland from 2011 to 2018. Adjusted hazard ratios (HRs) for IS, intracranial haemorrhage (ICH), bleeding, and mortality were calculated for dabigatran ( Conclusion: DOACs with reduced doses are efficient and safe stroke prevention therapy in high-risk patients with AF when compared with warfarin therapy of sufficient TTR. In this comparison, warfarin therapy of excellent TTR-quality was associated with the lowest risk of bleeding and mortality.

Indexed as

Atrial fibrillationIschaemic strokeOral anticoagulationReduced dose direct oral anticoagulants

Identifiers

PMID40357260
PMCPMC12066950

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.